Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Interest Expenses (2025)

Soleno Therapeutics (SLNO) has disclosed Interest Expenses for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest Expenses changed N/A to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a N/A change, with the full-year FY2025 number at $5.5 million, up 2270.56% from a year prior.
  • Interest Expenses was $1.3 million for Q4 2025 at Soleno Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.4 million in Q3 2025 to a low of $1.3 million in Q4 2025.